Bacopa
Also known as: Bacopa monnieri, Brahmi, Bacumen, Bacoside-A, Water Hyssop
Effective Dosage
300-600 mg/day (higher doses may be needed for memory benefits)
What the Science Says
Bacopa monnieri is a plant used for centuries in Ayurvedic medicine as a brain tonic. Clinical trials suggest it may improve working memory and short-term memory in healthy adults, particularly at doses of 600 mg or more per day, and may reduce stress and mental fatigue during cognitively demanding tasks. Benefits for memory appear to favor higher doses and may take 8–12 weeks to emerge.
What It Doesn't Do
Won't sharpen your focus or attention in most clinical trials — those outcomes consistently came back negative. Doesn't improve sleep quality. No proven effect on processing speed or sustained attention. Not a treatment for dementia or Alzheimer's disease — trials in mild cognitive impairment show mixed and limited results. The cancer-fighting angle seen in lab studies has zero human evidence.
Evidence-Based Benefits
Bacopa monnieri shows mixed results for cognitive function. A 12-week RCT (PMID 41091332) found no improvement in verbal learning, attention, or working memory versus placebo, but did find reductions in self-reported stress reactivity and post-task fatigue. A trial in mild cognitive impairment patients (PMID 38538390) found improvements in attention and verbal fluency at 2 months, though overall cognitive scores were only marginally significant. A network meta-analysis (PMID 41678913) suggests high-dose Brahmi (≥600 mg/day) may outperform lower doses and Ginkgo biloba for working memory and short-term memory in healthy adults, though direct head-to-head trial data are limited.
Weak EvidenceEffective at: 300-600 mg/day (higher doses may be needed for working memory benefits; see PMID 41678913)
Source: auto-research
Absorption & Bioavailability
Unknown — no pharmacokinetic data provided in the supplied studies. Standardized extracts (bacosides) are commonly used in trials, but absorption data is not reported.
Red Flags to Watch For
- Digestive complaints (nausea, upset stomach) and headaches were reported more frequently in Bacopa groups than placebo in a 2025 RCT
- Most positive memory findings come from higher doses (≥600 mg/day) — many products sell 300 mg or less, which may be insufficient
- Network meta-analyses include indirect comparisons, not head-to-head trials — rankings like '100% SUCRA' can be misleading to consumers
- Lab studies on cancer cells (glioblastoma) are purely pre-clinical and should not be used to market Bacopa as an anti-cancer supplement
- An ongoing trial in amnestic MCI has not yet reported results — claims about Alzheimer's prevention are premature
Products Containing Bacopa
See how Bacopa is used in these analyzed products:
Research Sources
- PubMed
- NIH DSLD
This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-04-06